JNJ JOHNSON & JOHNSON
Company Analysis
Latest News
Johnson & Johnson's second quarter 2026 revenue of $25.3B beats estimates as the company raises its full-year outlook.
Johnson & Johnson reported second quarter 2026 revenue of $25.31 billion, up 6.6% year-over-year, and adjusted EPS of $2.90, an increase of 4.7%. The results...
Johnson & Johnson Q2 2026 Earnings Preview: What Analysts Expect on July 15, 2026
For the second quarter of 2026, analysts expect Johnson & Johnson to report consensus revenue of $25.18 billion and adjusted EPS of $2.85, with the stock...
Johnson & Johnson's $45 Million Talc Verdict Upheld by Illinois Appellate Court
The Illinois Appellate Court upheld a $45 million verdict against Johnson & Johnson and its consumer-health spinoff, Kenvue. An original jury found that...
J&J Secures FDA Approval for Dual-Energy Cardiac Ablation Platform
Johnson & Johnson secured FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform. The system allows electrophysiologists to toggle between...
🟢 JNJ is trading 3.5% up today, driven by positive clinical trial results and a significant investment
• Shares are currently trading at $268.46, up 3.5%, rebounding sharply from the prior session’s decline. • Johnson & Johnson highlighted positive primary...
Johnson & Johnson Talc Lawsuit Ends in Mistrial as Jury Deadlocks
A Johnson & Johnson lawsuit in Los Angeles Superior Court ended in a mistrial after the jury failed to reach a unanimous verdict. Brad Yandell brought the...
🟢 JNJ soars 3.6% on positive EU drug recommendation and healthcare sector rotation
JNJ is trading 3.6% up at $253.75 today, driven by a positive recommendation from the European Medicines Agency (EMA) for an indication extension of its drug...
J&J Rejects Obesity Drug Market, Aiming for 2030 Cancer Leadership
CEO Joaquin Duato announced Johnson & Johnson will not develop GLP-1 drugs for the obesity market. The company will instead focus on sectors where it maintains...
Johnson & Johnson invests $1B in Florida, scaling ACUVUE production
Johnson & Johnson is investing over $1 billion to expand its vision care manufacturing and distribution operations in Jacksonville, Florida. The project will...
Johnson & Johnson Myeloma Combo Shows 89% Survival in Phase 3
Johnson & Johnson reported positive Phase 3 MonumenTAL-3 results for a combination therapy treating relapsed or refractory multiple myeloma. The study...
J&J eyes first-ever rare blood treatment approval after positive Imaavy data
Johnson & Johnson presented Phase 2/3 ENERGY study results for Imaavy (nipocalimab) at the European Hematology Association 2026 Congress. The therapy targets...
J&J Signals Faster Growth, Led by 4,500 New ICOTYDE Drug Prescribers
Johnson & Johnson executive Tom Cavanaugh provided a data-rich update at the Goldman Sachs Global Healthcare Conference on June 9. He signaled that the...
Johnson & Johnson buys Firefly Bio for $1B, targeting difficult tumors
Johnson & Johnson will acquire biotechnology firm Firefly Bio for $1 billion in cash. The deal integrates Firefly’s degrader antibody conjugate (DAC) platform...
Johnson & Johnson Reports 71% Myeloma Risk Reduction at ASCO 2026
Johnson & Johnson presented clinical trial results for its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) meeting. The Phase 3...
Johnson & Johnson Wins California Talc Trial, Defeating Ovarian Cancer Claims
A Los Angeles jury cleared Johnson & Johnson of negligence on June 5, 2026. The verdict rejected claims that the company’s talc-based powders caused fatal...
🟢 Johnson & Johnson is trading 3.1% up today on defensive rotation as broader market slides
Johnson & Johnson is trading 3.1% up at $235.13 as investors rotate into defensive healthcare stocks amid a broader market decline. • The gain comes despite...
J&J Recalls Abiomed Catheter Kits Over Serious Blood Clot Risks
The U.S. Food and Drug Administration (FDA) issued an early safety alert for specific catheter introducer kits manufactured by Johnson & Johnson’s Abiomed...
Johnson & Johnson Advances Nipocalimab, First FcRn Blocker to Succeed in Lupus
Johnson & Johnson announced that its investigational therapy, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for systemic lupus...
Johnson & Johnson Recalls Impella Heart Pumps, Linked to Patient Death
Johnson & Johnson’s Abiomed division recalled specific Impella CP with SmartAssist heart pumps. An internal review found that certain units failed to meet...
J&J’s Erleada Cuts Prostate Cancer Death Risk, Meeting Phase 3 Goals
Johnson & Johnson reported positive Phase 3 PROTEUS study results for its prostate cancer drug Erleada (apalutamide). The trial evaluated Erleada combined with...